移植肠的屏障功能损伤是造成小肠移植术后感染高发的重要原因。目前对小肠移植术后肠屏障功能的变化特点认识不足，控制感染还处于单纯强调杀灭病原体的阶段，缺乏具有针对性的改善肠屏障功能的手段。 以人源化CD52单克隆抗体（CD52 mAb）为基础的新型免疫诱导方案开始应用于小肠移植，但关于其对移植肠的局部作用并不清楚。 本项目拟建立小鼠原位小肠移植模型，观察移植肠屏障功能的变化规律以及CD52 mAb对其的影响。以肠上皮内淋巴细胞数量和功能变化为切入点，阐明CD52 mAb影响肠屏障功能的相关机制。并进一步探讨外源性角质细胞生长因子（KGF）能否逆转CD52 mAb对肠屏障的作用。 本项目深入研究CD52 mAb对移植肠屏障功能的作用，从改善肠屏障方面为控制小肠移植术后感染提供新的思路。小鼠原位小肠移植模型的建立，为今后相关研究提供理想的动物模型平台。

The injury to the intestinal mucosal barrier is associated with infections after small bowel transplantation (SBT). The change of the grafted intestinal barrier is elusive till now, therefore there is few targeted means to improve intestinal barrier and the use of anti-microbial agents is the primary method to control infection. Tolerance-inducing immunosuppressive strategy by humanized anti-CD52 monoclonal antibody (CD52 mAb) is used in clincal SBT. While the local effect to the grafted intestine of this antibody is still unknow. This research is plan to observe the change of the grafted intestinal barrier after CD52 mAb application in a murine orthotopic SBT model, to clarify the mechanism considering intra-epithelial lymphocyte, and to investigate whether exogenous Keratinocyte growth factor ( KGF ) can reverse the effect of CD52 mAb. This research is to study the effect of CD52 mAb on the grafted intestinal barrier, and provide new ideas how to control infection after SBT by improving intestinal barrier. The murine orthotopic SBT model is an ideal animal model for future research.